Results 1 to 10 of about 11,608,610 (402)

Epidemiology of chronic kidney disease: an update 2022

Kidney International Supplements, 2022
Csaba Kovesdy
exaly   +2 more sources

Serum PTH Associated with Malnutrition Determined by Bioelectrical Impedance Technology in Chronic Kidney Disease Patients

International Journal of Endocrinology, 2022
Purpose. Chronic malnutrition and cachexia are common in chronic kidney disease (CKD), and importance should be given to these complications because they affect the patient’s quality of life and prognosis.
Lilin Liu, Lulu Wang, Xiao Wang, Mingxia Xiong, Hongdi Cao, Lei Jiang, Junwei Yang   +6 more
doaj   +1 more source

Prescription characteristics of phosphate binders in a high pill burden for hemodialysis patients

Renal Replacement Therapy, 2021
Background Dialysis patients have to take many oral drugs, causing a high pill burden. Phosphate binders (PBs) account for a large proportion of daily pill burden; however, the relationship between patient background and prescription status of PBs is not
Nobuo Nagano, Kyoko Ito, Takashi Ono, Yuichi Ariyoshi, Soichiro Masima, Hajime Kobayashi, Tetsuo Ando, Takaaki Tsutsui, Tetsuya Ogawa   +8 more
doaj   +1 more source

Successful treatment of nephrotic syndrome due to pregnancy-related crescentic IgA nephropathy: a case report

BMC Nephrology, 2023
Background Crescentic immunoglobulin A (IgA) nephropathy, defined as > 50% of the glomeruli with crescents, often has a poor renal prognosis. Because of the high prevalence of pre-eclampsia in the second trimester of pregnancy, we often fail to ...
Hisato Shima, Toshio Doi, Takuya Okamoto, Tomoko Inoue, Manabu Tashiro, Seiichiro Wariishi, Kazuhiko Kawahara, Kazuyoshi Okada, Jun Minakuchi   +8 more
doaj   +1 more source

Empagliflozin in Patients with Chronic Kidney Disease

New England Journal of Medicine, 2022
Background This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. Methods We randomly assigned 6609 participants to empagliflozin (10mg
W. Herrington, N. Staplin, C. Wanner, J. B. Green, S. Hauske, J. Emberson, D. Preiss, P. Judge, Kaitlin J. Mayne, S. Ng, E. Sammons, D. Zhu, M. Hill, W. Stevens, K. Wallendszus, S. Brenner, A. Cheung, Zhi-Hong Liu, Jing Li, L. Hooi, Wen Liu, T. Kadowaki, M. Nangaku, A. Levin, D. Cherney, A. Maggioni, R. Pontremoli, R. Deo, S. Goto, X. Rosselló, K. Tuttle, D. Steubl, M. Petrini, D. Massey, Jens Eilbracht, M. Brueckmann, M. Landray, C. Baigent, R. Haynes   +38 more
semanticscholar   +1 more source

A retrospective study of patients with Stenotrophomonas maltophilia peritonitis undergoing peritoneal dialysis

Renal Replacement Therapy, 2023
Background Stenotrophomonas maltophilia (S. maltophilia) is being increasingly recognized as an important cause of nosocomial infections, particularly in immunocompromised patients, such as patients undergoing dialysis. S.
Hisato Shima, Takuya Okamoto, Manabu Tashiro, Tomoko Inoue, Maho Iwaki, Seiichiro Wariishi, Kazuyoshi Okada, Toshio Doi, Jun Minakuchi   +8 more
doaj   +1 more source

Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease

BMC Nephrology, 2021
Background Minimal change disease is a common cause of nephrotic syndrome in adults. Higher relapse rate put patients at risk of steroids toxicity due to long-term exposure.
Diankun Liu, Zhanmei Zhou, Mengyi Wang, Sheng Nie, Jun Li, Bianxiang Hu, Wenjuan He, Guobao Wang, Jun Ai   +8 more
doaj   +1 more source

Dapagliflozin in Patients with Chronic Kidney Disease.

New England Journal of Medicine, 2020
BACKGROUND Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.
H. Heerspink, B. Stefánsson, R. Correa-Rotter, G. Chertow, T. Greene, F. Hou, J. Mann, J. McMurray, M. Lindberg, P. Rossing, C. Sjöström, R. Toto, A. Langkilde, D. Wheeler   +13 more
semanticscholar   +1 more source

The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

Journal of Diabetes Research, 2021
Background and Aim. Strong evidence exists supporting the utility of sodium glucose cotransporter inhibitors (SGLT2is) for treating not only cardiovascular events but also renal events.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Kazuyoshi Sato, Masaaki Miyakawa, Kouichi Tamura, Akira Kanamori   +6 more
doaj   +1 more source

Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)

Diabetes Care, 2022
People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure, atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent clinical trials support new approaches to treat diabetes and CKD.
I. D. de Boer, K. Khunti, Tami Sadusky, K. Tuttle, Joshua J. Neumiller, Connie M. Rhee, Sylvia E. Rosas, P. Rossing, G. Bakris   +8 more
semanticscholar   +1 more source